Literature DB >> 17381072

Combining the influence of two low O2 affinity-inducing chemical modifications of the central cavity of hemoglobin.

Parimala Nacharaju1, Joel M Friedman, Muthuchidambaram Prabhakaran, Seetharama A Acharya, Belur N Manjula.   

Abstract

HexaPEGylated hemoglobin (Hb), a non-hypertensive Hb, exhibits high O2 affinity, which makes it difficult for it to deliver the desired levels of oxygen to tissues. The PEGylation of very low O2 affinity Hbs is now contemplated as the strategy to generate PEGylated Hbs with intermediate levels of O2 affinity. Toward this goal, a doubly modified Hb with very low O2 affinity has been generated. The amino terminal of the beta-chain of HbA is modified by 2-hydroxy, 3-phospho propylation first to generate a low oxygen affinity Hb, HPPr-HbA. The oxygen affinity of this Hb is insensitive to DPG and IHP. Molecular modeling studies indicated potential interactions between the covalently linked phosphate group and Lys-82 of the trans beta-chain. To further modulate the oxygen affinity of Hb, the alpha alpha-fumaryl cross-bridge has been introduced into HPPr-HbA in the mid central cavity. The doubly modified HbA (alpha alpha-fumaryl-HPPr-HbA) exhibits an O2 affinity lower than that of either of the singly modified Hbs, with a partial additivity of the two modifications. The geminate recombination and the visible resonance Raman spectra of the photoproduct of alpha alpha-fumaryl-HPPr-HbA also reflect a degree of additive influence of each of these modifications. The two modifications induced a synergistic influence on the chemical reactivity of Cys-93(beta). It is suggested that the doubly modified Hb has accessed the low affinity T-state that is non-responsive to effectors. The doubly modified Hb is considered as a potential candidate for generating PEGylated Hbs with an O2 affinity comparable to that of erythrocytes for developing blood substitutes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17381072      PMCID: PMC2572862          DOI: 10.1021/bi0621462

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  59 in total

1.  Site-directed mutagenesis in hemoglobin: test of functional homology of the F9 amino acid residues of hemoglobin alpha and beta chains.

Authors:  A H Mawjood; G Miyazaki; R Kaneko; Y Wada; K Imai
Journal:  Protein Eng       Date:  2000-02

2.  Activation of the low oxygen affinity-inducing potential of the Asn108(beta)-->Lys mutation of Hb-Presbyterian on intramolecular alpha alpha-fumaryl cross-bridging.

Authors:  B N Manjula; A Malavalli; M Prabhakaran; J M Friedman; A S Acharya
Journal:  Protein Eng       Date:  2001-05

3.  Beta 93 modified hemoglobin: kinetic and conformational consequences.

Authors:  I Khan; D Dantsker; U Samuni; A J Friedman; C Bonaventura; B Manjula; S A Acharya; J M Friedman
Journal:  Biochemistry       Date:  2001-06-26       Impact factor: 3.162

4.  Determination of the reactive sulfhydryl groups in heme proteins with 4,4'-dipyridinedisulfide.

Authors:  R S Ampulski; V E Ayers; S A Morell
Journal:  Anal Biochem       Date:  1969-10-15       Impact factor: 3.365

5.  Mechanism for the increase in solubility of deoxyhemoglobin S due to cross-linking the beta chains between lysine-82 beta 1 and lysine-82 beta 2.

Authors:  R Chatterjee; R Y Walder; A Arnone; J A Walder
Journal:  Biochemistry       Date:  1982-11-09       Impact factor: 3.162

6.  Comparison of the effects of a 50% exchange-transfusion with albumin, hetastarch, and modified hemoglobin solutions.

Authors:  Wilfred Lieberthal; Robert Fuhro; Hasan Alam; Peter Rhee; Janos Szebeni; Herbert B Hechtman; Joanne Favuzza; Richard L Veech; C Robert Valeri
Journal:  Shock       Date:  2002-01       Impact factor: 3.454

7.  MP4, a new nonvasoactive PEG-Hb conjugate.

Authors:  Kim D Vandegriff; Ashok Malavalli; Jerod Wooldridge; Jeff Lohman; Robert M Winslow
Journal:  Transfusion       Date:  2003-04       Impact factor: 3.157

8.  Myoglobin as a model system for designing heme protein based blood substitutes.

Authors:  Yi Dou; David H Maillett; Raymund F Eich; John S Olson
Journal:  Biophys Chem       Date:  2002-07-10       Impact factor: 2.352

Review 9.  Oxygen-carrying blood substitutes: a microvascular perspective.

Authors:  Amy G Tsai; Pedro Cabrales; Marcos Intaglietta
Journal:  Expert Opin Biol Ther       Date:  2004-07       Impact factor: 4.388

10.  Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics.

Authors:  Amy G Tsai; Kim D Vandegriff; Marcos Intaglietta; Robert M Winslow
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-06-12       Impact factor: 4.733

View more
  2 in total

1.  Hexa-thiocarbamoyl phenyl PEG5K Hb: vasoactivity and structure: influence of rigidity of the conjugation linkage on the PEGylation induced plasma expander-like solution properties of PEG-Hb adducts.

Authors:  Fantao Meng; Belur N Manjula; Amy G Tsai; Pedro Cabrales; Marcos Intaglietta; Paul K Smith; Muthuchidambaram Prabhakaran; Seetharama A Acharya
Journal:  Protein J       Date:  2009-06       Impact factor: 2.371

2.  PEGylation of αα-Hb using succinimidyl propionic acid PEG 5K: Conjugation chemistry and PEG shell structure dictate respectively the oxygen affinity and resuscitation fluid like properties of PEG αα-Hbs.

Authors:  Fantao Meng; Amy G Tsai; Marcos Intaglietta; Seetharama A Acharya
Journal:  Artif Cells Nanomed Biotechnol       Date:  2014-03-06       Impact factor: 5.678

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.